登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>BCMA >BCA-M82F0

Biotinylated Mouse BCMA / TNFRSF17 Protein, Fc,Avitag™

热销产品推荐:

利用生物素-链霉亲和素系统的高特异性和高灵敏度的结合特性,可将生物素化蛋白与链霉亲和素相关产品联合应用于各类实验,与非生物素体系相比,检测速度更快、结合能力更强、非特异背景更低。

分子别名(Synonym)

TNFRSF17,CD269,BCM,BCMA

表达区间及表达系统(Source)

Biotinylated Mouse BCMA, Fc,Avitag (BCA-M82F0) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Thr 49 (Accession # O88472-1).

Predicted N-terminus: Met 1

Request for sequence

蛋白结构(Molecular Characterization)

BCMA Structure

This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 34.4 kDa. The protein migrates as 38-43 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to O-linked glycosylation which has been verified by O-Glycosidase and Neuraminidase digestion.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

BCMA SDS-PAGE

Biotinylated Mouse BCMA, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

 

活性(Bioactivity)-ELISA

BCMA ELISA

Immobilized Mouse BAFF, Mouse IgG2a Fc Tag (Cat. No. BAF-M5257) at 5 μg/mL (100 μL/well) can bind Biotinylated Mouse BCMA, Fc,Avitag (Cat. No. BCA-M82F0) with a linear range of 2-39 ng/mL (QC tested).

Protocol

BCMA ELISA

Immobilized Biotinylated Mouse BCMA, Fc,Avitag (Cat. No. BCA-M82F0) at 1 μg/mL (100 μL/well) on Recombinant Streptavidin (Cat. No. STN-N5116) precoated (0.5μg/well) plate, can bind Human APRIL, His,Flag Tag, active trimer (Cat. No. APL-H52D1) with a linear range of 10-78 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

BCMA BLI

Loaded Biotinylated Mouse BCMA, Fc,Avitag (Cat. No. BCA-M82F0) on SA Biosensor, can bind Mouse BAFF, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. BAF-M5257) with an affinity constant of 3.75 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

BCMA BLI

Loaded Biotinylated Mouse BCMA, Fc,Avitag (Cat. No. BCA-M82F0) on SA Biosensor, can bind Human APRIL, His,Flag Tag, active trimer (Cat. No. APL-H52D1) with an affinity constant of 2.19 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

背景(Background)

Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
BCMA靶点信息
英文全称:B-cell maturation protein
中文全称:B细胞成熟蛋白
种类:Homo sapiens
上市药物数量:6详情
临床药物数量:89详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定